WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug ...
Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated ...
Co announces that the FDA has granted final approval for the Company's Abbreviated New Drug Application for Rabeprazole Sodium Delayed-Release Tablets, 20 mg. TEVA's Rabeprazole Sodium Delayed-Release ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback